- Login
- Manage Portfolio
- Post a StockTalk
- Write an Instablog
- Get Daily Email Alert
-
Seeking Alpha
-
Friday, November 20th
Expiration Trade Behind Osiris Activity
-
BioMed News Bytes: AstraZeneca, Delcath, Unilife
-
A Possible New Indication for Progenix's Relistor Could Revive Its Fortunes
-
Santarus' Zegrid Facing Back-to-Back FDA Approval Dates
-
Competition in Blood - Thinners: Win - Win for Everyone Involved
-
Thursday, November 19th
Echo Therapeutics: Positive Developments for a Needle-Free Diabetes Monitoring System
-
Oral-lyn vs. Afresa: How Generex Will Beat Mannkind
-
Cheating Death: Possible Winners and Losers in Life Extension Strategies
-
Wednesday, November 18th
Biotech Stocks for a Possible Year-End Rally
-
BioMed News Bytes: GeoVax, Cerus, Discovery Labs, NeurogesX
-
Tuesday, November 17th
Lumizyme Rejected Again: Downgrading Genzyme Recommendation from Buy to Hold
-
BioMed News Bytes: Cytori, Poniard, Alkermes, Spherix, CRXX, HGSI
-
Monday, November 16th
Cholesterol Drug Trials: A Victory for Abbott Means a Loss for Merck
-
Santarus, Depomed Poised to Gain from Anticipated Sales of Glumetza
-
Playing the Options Game in RIM; Cel Sci Not Yet Trading to Its Potential
-
ISIS' Short-Term Trends Demonstrate When Technical Analysis Is Important
-
Don't Like Celsius Holdings? Try Cel-Sci Instead
-
Developments for Parkinson's Disease Ignite Investor Enthusiasm
-
Sunday, November 15th
Sanofi-Aventis to Establish Venture Capital Fund, Looking for 'Right Brain Activity'
-
Big Pharma Willing to Pay for Biotech Innovation
-
Thursday, November 12th
Why Has Cel-Sci Quietly Amended Some Previously Filed Paperwork?
-
American Oriental Bioengineering: Questionable Acquisitions
-
Cytokinetics' Market Potential
-
Wednesday, November 11th
Lexicon Pharmaceuticals: Stuck in Phase II?
-
Chelsea Therapeutics: There Are Safer Rebound Plays